All In Biotech

Drug Trial Radar · NCT03422536

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Dec 5, 2017

Primary completion

Mar 29, 2022

Study completion Apr 5, 2022

Sponsor

Lead sponsor
University of ArizonaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Feb 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase II trial studies how well ficlatuzumab with or without cetuximab works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body and resistant to cetuximab treatment. Monoclonal antibodies, such as ficlatuzumab and cetuximab, may block growth signals that lets a tumor cell survive and reproduce, and helps the immune system recognize and fight head and neck squamous cell carcinoma.

Conditions

  • Head and Neck Basaloid Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Recurrent Oropharyngeal Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Unknown Primary Origin
  • Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
  • Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma
  • Stage IV Oropharyngeal Squamous Cell Carcinoma
  • Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma
  • Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
  • Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma
  • Stage IVA Oropharyngeal Squamous Cell Carcinoma
  • Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma
  • Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
  • Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma
  • Stage IVB Oropharyngeal Squamous Cell Carcinoma
  • Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma
  • Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
  • Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma
  • Stage IVC Oropharyngeal Squamous Cell Carcinoma
  • Head and Neck Cancer
  • Oropharyngeal Cancer
  • HNSCC
  • Stage IV Lip and Oral Cavity Squamous Cell Carcinoma

Interventions

  • CetuximabBiological

    Given IV

  • FiclatuzumabDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From the date of randomization until the date of progression or death, assessed up to 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • Yale Cancer Center

    New Haven, Connecticut

  • Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.